SciSparc (SPRC) Stock Price, News & Analysis

Company Overview

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function. By harnessing acoustic pressure waves, the TR100 aims to promote neurogenesis and synaptic plasticity without the need for surgical intervention. SciSparc has obtained CE marking for its tSWS platform in the European Union and is actively pursuing clinical trials in indications such as post‐stroke motor rehabilitation, treatment‐resistant depression and other neurological disorders.

Serving both European and North American markets, SciSparc collaborates with academic institutions and clinical research centers to validate safety and efficacy in human subjects. Its Swiss headquarters oversees research and development, regulatory affairs and manufacturing partnerships, while its U.S. operations concentrate on clinical development and market access strategies. By integrating neuroscience research with advanced engineering, SciSparc aims to expand the availability of noninvasive neuromodulation therapies on a global scale.

Key Stats

• Today's Range: $4.32 to $4.62
• 50-Day Range: $1.80 to $6.09
• 52-Week Range: $1.75 to $37.59
• Volume: 55,687 shs
• Average Volume: 1.66 million shs
• Market Capitalization: $2.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

SciSparc Stock Analysis - MarketRank™

SciSparc scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for SciSparc.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

SciSparc has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

22.75% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 19.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SciSparc does not currently pay a dividend.

Dividend Growth

SciSparc does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

22.75% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 19.42%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.67

News Sentiment

SciSparc has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for SciSparc this week, compared to 2 articles on an average week.

Search Interest

10 people have searched for SPRC on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

2 people have added SciSparc to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SciSparc insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.52% of the stock of SciSparc is held by insiders.

Percentage Held by Institutions

Only 25.06% of the stock of SciSparc is held by institutions.

SPRC Stock Analysis - Frequently Asked Questions

How have SPRC shares performed this year?

SciSparc's stock was trading at $7.56 on January 1st, 2025. Since then, SPRC stock has decreased by 41.9% and is now trading at $4.39.

When did SciSparc's stock split?

Shares of SciSparc reverse split on the morning of Thursday, July 3rd 2025.The 1-21 reverse split was announced on Tuesday, June 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of SciSparc?

Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SciSparc own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SciSparc investors own include Solid Power (SLDP), Sangamo Therapeutics (SGMO), Plug Power (PLUG), NVIDIA (NVDA), Verb Technology (VERB) and Avalon GloboCare (ALBT).

Company Calendar

• Today: 10/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRC
• CIK: 1611746
• Web: scisparc.com
• Phone: 972-3717-5777
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.31 million
• Price / Sales: 1.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.13 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 535,000
• Free Float: 527,000
• Market Cap: $2.37 million
• Optionable: Not Optionable
• Beta: 1.15